Transcriptional intermediary factor 1 gamma-based multitarget gene therapeutic strategy for triple-negative breast cancer
Triple-negative breast cancer (TNBC) is an aggressive subtype lacking effective targeted therapies. A multitarget gene therapy was developed and validated to overcome molecular heterogeneity and compensatory survival signaling in TNBC. A codon-optimized human transcriptional intermediary factor 1 gamma (opti-hTIF1γ) ge...